Table 1.
Characteristics of patients
| Patients No | B001 | B002 | B003 | B004 | B005 | B006 | B007 | B008 |
|---|---|---|---|---|---|---|---|---|
| Gender | Male | Male | Male | Male | Male | Male | Male | Male |
| Age (years) | 49 | 51 | 59 | 48 | 46 | 67 | 56 | 59 |
| AST (IU/L) at baseline | 28 | 44 | 71 | 71 | 26 | 42 | 80 | 19 |
| ALT (IU/L) at baseline | 22 | 36.5 | 40 | 48 | 26 | 27.5 | 28 | 13 |
| Total bilirubin (μmol/L) at baseline | 8.5 | 43.3 | 18 | 21.7 | 7.5 | 11.1 | 15.3 | 10.1 |
| Platelet counts (109/L) at baseline | 230 | 24 | 77 | 173 | 160 | 192 | 276 | 147 |
| HBV‐TCRs (HBV‐Env) | HLA‐A0201 | HLA‐A0201 | HLA‐A0201 | HLA‐Cw0801 | HLA‐A0201 | HLA‐A0201 | HLA‐A0201 | HLA‐A0201 |
| HBV genotype | C | – | C | C | – | – | – | |
| HBsAg serum (IU/ml) | 202 | 1444 | 929.9 | 210.9 | 942.6 | 1549 | 231.5 | 303.8 |
| HBeAg status | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Negative |
| HBeAb status | Positive | Positive | Positive | Positive | Positive | Positive | Positive | Positive |
| Circulating HBV DNA (IU/ml) at baseline | 499 | < 40 | 458 | 991 | < 20 | 44.2 | < 20 | < 20 |
| Epitope sequence at baseline | FLLTRILTI | – | FLLTRILTI | FLGPLLVLQA | – | – | – | – |
| Circulating HBV DNA (IU/ml) after TCR-T-cell infusions | 30.5 | < 40 | 318 | 492 | < 40 | < 20 | < 20 | < 20 |
| Epitope sequence after TCR-T-cell infusions | – | – | FLLTRILTI | FLGPLLVLQA | – | – | – | – |
| AFP ≥ 400 ng per milliliter | No | No | No | Yes | No | No | Yes | No |
| ECOG performance status score | 1 | 1 | 2 | 2 | 0 | 1 | 1 | 1 |
| Child–Pugh classification (score) | A5 | B8 | A6 | B9 | A5 | A6 | A6 | A6 |
| BCLC stage | C | B | C | C | C | A | C | C |
| Tumor in liver (size, max, cm & number) | Multiple (13.9 × 6.9) | Multiple (3.5 × 1.9) | Multiple (4.8 × 13.1) | Multiple (17.9 × 12.1) | 2 (3.9 × 3.4) | 1 (3.2 × 3.07) | Multiple (11.5 × 9.3) | 2 (3.8 × 3.2) |
| Presence of Macrovascular invasion | Yes | No | Yes | Yes | No | No | No | No |
| Presence of Extrahepatic spread | Yes | No | Yes | Yes | Yes | No | Yes | Yes |
| Antiviral treatment | Entecavir | Entecavir | Entecavir | Entecavir | Entecavir | Entecavir | Entecavir | Entecavir |
| Prior treatment for HCC | TACE + Sorafenib | TACE + Sorafenib | RFA | Sorafenib | TACE + Sorafenib | TACE + RFA | Sorafenib | Argon-helium knife therapy for HCC + RFA + Sorafenib |
| Combination therapy | Sorafenib | Sorafenib | Sorafenib | Sorafenib | Sorafenib + 1 RFA | 1 Microwave ablation | Sorafenib | Sorafenib |
| Therapy after TCR-T-cell infusion | Sorafenib | Sorafenib + Lenvatinib + 2 TACE | Sorafenib | Sorafenib | Sorafenib + 1 RFA | no | Sorafenib | Sorafenib |
AST aspartate aminotransferase, ALT alkaline phosphatase; HBV hepatitis B virus, HBsAg hepatitis B surface antigen, HBeAg hepatitis B e-antigen, AFP α-fetoprotein; ECOG Eastern Cooperative Oncology Group, BCLC Barcelona clinic liver cancer (BCLC) stage, TACE transcatheter arterial chemoembolization; RFA radiofrequency ablation